To market, to market - 1995

[1] ABRAMOWICZ M, 1995, MED LETT DRUGS THER, V37, P75

[2] EFFICACY AND SAFETY PROFILE OF GEMCITABINE IN NON-SMALL-CELL LUNG-CANCER - A PHASE-II STUDY [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (08) : 1535 - 1540

[3] Agarwal M. B., 1992, Drugs of Today, V28, P107

[4] ALLISON AC, 1993, AGENT ACTION SUPPL, V44, P165

[5] IMMUNOSUPPRESSIVE AND OTHER EFFECTS OF MYCOPHENOLIC-ACID AND AN ESTER PRODRUG, MYCOPHENOLATE MOFETIL [J]. IMMUNOLOGICAL REVIEWS, 1993, 136 : 5 - 28

[6] ALSAKA K, 1992, JPN J PHARMACOL, V59, P489

[7] [Anonymous], BREAST CANC RES TREA

[8] ASANO T, 1987, J PHARMACOL EXP THER, V241, P1033

[9] ASANO T, 1990, METHOD FIND EXP CLIN, V12, P443

[10] PRECLINICAL PHARMACOLOGY OF DOCETAXEL [J]. EUROPEAN JOURNAL OF CANCER, 1995, 31A : S1 - S6

[1] ABRAMOWICZ M, 1995, MED LETT DRUGS THER, V37, P75

[2] EFFICACY AND SAFETY PROFILE OF GEMCITABINE IN NON-SMALL-CELL LUNG-CANCER - A PHASE-II STUDY [J]. JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (08) : 1535 - 1540

[3] Agarwal M. B., 1992, Drugs of Today, V28, P107

[4] ALLISON AC, 1993, AGENT ACTION SUPPL, V44, P165

[5] IMMUNOSUPPRESSIVE AND OTHER EFFECTS OF MYCOPHENOLIC-ACID AND AN ESTER PRODRUG, MYCOPHENOLATE MOFETIL [J]. IMMUNOLOGICAL REVIEWS, 1993, 136 : 5 - 28

[6] ALSAKA K, 1992, JPN J PHARMACOL, V59, P489

[7] [Anonymous], BREAST CANC RES TREA

[8] ASANO T, 1987, J PHARMACOL EXP THER, V241, P1033

[9] ASANO T, 1990, METHOD FIND EXP CLIN, V12, P443

[10] PRECLINICAL PHARMACOLOGY OF DOCETAXEL [J]. EUROPEAN JOURNAL OF CANCER, 1995, 31A : S1 - S6